The deletion of CDKN2A was not only a diagnostic marker for a poor clinical outcome, but also it predicts metastasis of pancreatic tumor [52], recurrence of oral squamous cell carcinoma [53], and early recurrence in meningioma [54,55]. This evidence concerns the gene CDKN2A and pancreatic neoplasm.